Takeda Pharmaceutical Co Ltd ADR

Yahoo Finance • 4 days ago

H.C. Wainwright Raises Protagonist Therapeutics, Inc. (PTGX) Target to $117, Reiterates Buy

We recently published an article titled 10 Best Long Term Healthcare Stocks to Buy. On January 30, H.C. Wainwright raised its price target on Protagonist Therapeutics, Inc. (NASDAQ:PTGX) to $117 from $80 and reiterated a Buy rating. The f... Full story

Yahoo Finance • 5 days ago

U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 1

This FDA Acceptance is a Milestone for People Living with Narcolepsy Type 1 Who Need New and Different Treatment Options Oveporexton is an Orexin Agonist Designed to Restore Orexin Signaling and Address the Underlying Orexin Deficiency tha... Full story

Yahoo Finance • 13 days ago

Is Takeda’s Upgraded FY2025 Outlook And New PID Therapy Altering The Investment Case For Takeda (TSE:4502)?

In late January 2026, Takeda Pharmaceutical reported nine-month FY2025 results showing sales of ¥3,411.18 billions and net income of ¥216.08 billions, alongside slightly higher earnings per share year-on-year, and raised its full-year 2025... Full story

Yahoo Finance • 2 months ago

Blending Data and Local Knowledge To Enable Sustainable Outcomes

This interview is part of Takeda's Access to Medicine Report. Read the full interview here. NORTHAMPTON, MA / ACCESS Newswire / December 29, 2025 / In February 2024, Takeda entered into a partnership with CARE, a global leader in the figh... Full story

Yahoo Finance • 2 months ago

Weekly Buzz: CYTK Scores First FDA Approval, INSM Ends Rhinosinusitis Study, XOMA Acquires GBIO

(RTTNews) - The biotech industry witnessed several key events this week, including major FDA approvals, acquisitions, pivotal clinical trial results and setbacks. • A series of FDA approvals were announced during the week, with GSK, Haloz... Full story

Yahoo Finance • 2 months ago

Takeda posts late-stage trial win for oral plaque psoriasis therapy

[Takeda Pharmaceutical Company. Takeda recently acquired Irish drugmaker Shire I] jetcityimage/iStock Editorial via Getty Images Takeda (TAK [https://seekingalpha.com/symbol/TAK]) on Thursday announced that two pivotal late-stage trials f... Full story

Yahoo Finance • 2 months ago

Sen-Jam Pharmaceutical Secures Major Strategic Partnership with TASK Clinical to Fund Two-Thirds of Phase 3 Trial for SJP-001

Equity-backed commitment dramatically de-risks pivotal program, boosts licensing appeal, and strengthens commercialization readiness. HUNTINGTON, N.Y., Dec. 11, 2025 /PRNewswire/ -- Sen-Jam Pharmaceutical, a clinical-stage biotechnology c... Full story

Yahoo Finance • 2 months ago

Sen-Jam Pharmaceutical Appoints Global Life Sciences Leader Rute Fernandes as Executive Advisor to Accelerate Commercialization Pathways

HUNTINGTON, N.Y., Dec. 9, 2025 /PRNewswire/ -- Sen-Jam Pharmaceutical, a clinical-stage biopharmaceutical company pioneering first-in-class therapeutics for inflammation-driven conditions, today announced the appointment of Rute Fernandes... Full story

Yahoo Finance • 2 months ago

Protagonist And Takeda Report 52-Week Rusfertide Data In Polycythemia Vera

(RTTNews) - Protagonist Therapeutics, Inc. (PTGX) and Takeda (TAK) announced new 52-week results from the pivotal Phase 3 VERIFY study of rusfertide in patients with polycythemia vera (PV). The data, presented at the 67th American Society... Full story

Yahoo Finance • 2 months ago

Innovent, Takeda Close $11.4 Bln Collaboration To Advance Next-Generation IO And ADC Therapies

(RTTNews) - Innovent Biologics (IVBXF, 1801.HK) announced that its global strategic collaboration with Takeda (4502.T, TAK) has officially closed and become effective following the satisfaction of all closing conditions. The partnership, f... Full story

Yahoo Finance • 3 months ago

Gene Therapy Collaboration and Licensing Agreements Trends Analysis Report 2025 with Directory of 787 Deals Signed Since 2016 by Company A-Z, Therapy Focus and Technology Type

Dublin, Nov. 26, 2025 (GLOBE NEWSWIRE) -- The "Gene Therapy Collaboration and Licensing Deals 2016-2025" has been added to ResearchAndMarkets.com's offering. This report contains a comprehensive listing of 787 gene therapy deals anno... Full story

Yahoo Finance • 3 months ago

Hemophilia A Research Report 2025-2035: Market Driven by Innovation from Alnylam, Pfizer, Roche, Novo Nordisk, and Takeda as Next-Generation Therapies and Emerging Market Expansion Bolsters Growth

Dublin, Nov. 18, 2025 (GLOBE NEWSWIRE) -- The "Hemophilia A Market - A Global and Regional Analysis: Focus on Treatment Type, Country, and Region - Analysis and Forecast, 2025-2035" report has been added to ResearchAndMarkets.com's offe... Full story

Yahoo Finance • 3 months ago

Pharmaceuticals and Biotechnology Joint Venture Agreements Analysis Report 2025: Track Trends, Benchmark Valuations, and Access Detailed Contract Terms from 2016 Onward

Dublin, Nov. 18, 2025 (GLOBE NEWSWIRE) -- The "Joint Venture Deals in Pharmaceuticals and Biotechnology 2016-2025" has been added to ResearchAndMarkets.com's offering. This report contains a comprehensive listing of joint venture dea... Full story

Yahoo Finance • 3 months ago

Gaucher Disease Global Clinical Trials Market Review 2025: Trial Enrollment, Geographic Hotspots, and Prominent Drugs in Development

Dublin, Nov. 14, 2025 (GLOBE NEWSWIRE) -- The "Gaucher Disease - Global Clinical Trials Review, 2025" clinical trials has been added to ResearchAndMarkets.com's offering. The provides an overview of Gaucher Disease Clinical trials sc... Full story

Yahoo Finance • 3 months ago

High Concentration mAb Products Market Advancing Precision Biopharmaceutical Therapeutics – Towards Healthcare

Ottawa, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Drug products formulated with high concentrations of monoclonal antibodies (mAbs) represent a distinct and advanced class of biopharmaceuticals. These therapies are typically administered subcuta... Full story

Yahoo Finance • 4 months ago

European indexes mixed awaiting ECB interest rate decision

[Global Business Strategy on Digital Display] Tom Werner London (UKX [https://seekingalpha.com/symbol/UKX]) +0.61% to 9,756 Germany (DAX:IND [https://seekingalpha.com/symbol/DAX:IND]) -0.64% to 24,124. France (CAC:IND [https://seekingal... Full story

Yahoo Finance • 4 months ago

Takeda Pharmaceutical Non-GAAP EPS of ¥279.00, revenue of ¥2219.5B; updates FY outlook

* Takeda Pharmaceutical press release [https://seekingalpha.com/pr/20285631-takeda-reports-first-half-fy2025-results-with-business-fundamentals-tracking-as-planned] (TAK [https://seekingalpha.com/symbol/TAK]): 1H Non-GAAP EPS of ¥279.00.... Full story

Yahoo Finance • 4 months ago

Stifel Canada on Healwell AI's Darwen Platform

Healwell AI (AIDX.TO) this week, in collaboration with vedolizumab manufacturer, Takeda, presented n PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 4 months ago

Innovent inks $11.4 billion cancer drug partnership with Japan's Takeda

[Research and Educational Laboratory] SolStock/E+ via Getty Images China's Innovent Biologics (OTCPK:IVBIY [https://seekingalpha.com/symbol/IVBIY]) has inked a strategic global collaboration with Japan's Takeda (NYSE:TAK [https://seekinga... Full story

Yahoo Finance • 4 months ago

Takeda And Innovent Biologics Sign Global Oncology Collaboration Outside Greater China

(RTTNews) - Takeda (TAK) has signed a license and collaboration agreement with Innovent Biologics to advance the development, manufacturing, and commercialization of two late-stage oncology therapies—IBI363 and IBI343—across global market... Full story